🦴 Osteoporosis: Starting Anti-Osteoporosis Therapy
This tool decides whether to start anti-osteoporosis therapy and at what intensity, integrating fragility-fracture history, BMD T-score, and FRAX 10-year fracture probability.
A hip or vertebral fragility fracture diagnoses osteoporosis and triggers treatment independent of the BMD value. (original synthesis · not guideline verbatim)
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to triage treatment: a hip/vertebral fragility fracture or T-score ≤ -2.5 mandates therapy, while low bone mass is treated when accompanied by another fragility fracture or high FRAX risk.
How it works
Treat if hip/vertebral fragility fracture, T ≤ -2.5, or low bone mass (-2.5 < T ≤ -1.0) with another fragility fracture or FRAX major ≥ 20%/hip ≥ 3%. Very high risk (FRAX major > 30%/hip > 4.5%, T ≤ -3.0) selects more potent agents.
Key points
- A hip or vertebral fragility fracture diagnoses osteoporosis and triggers treatment independent of the BMD value. (original synthesis · not guideline verbatim)
- Very-high-risk patients are candidates for anabolic or more potent agents (teriparatide, romosozumab, denosumab, zoledronic acid).
- All patients receive calcium, vitamin D, weight-bearing exercise, fall prevention, and a secondary-cause workup.
References
- Chinese Society of Osteoporosis and Bone Mineral Research. Guideline for the diagnosis and treatment of primary osteoporosis (2022).
- Camacho PM, et al. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Hip or vertebral fragility-fracture history | Present |
|---|---|
| Fragility fracture at other sites | Present |
| BMD T-score (lowest site) | -2.7 |
| FRAX 10-year major osteoporotic fracture probability (optional) | 22 % |
| FRAX 10-year hip fracture probability (optional) | 3.5 % |
→DispositionImmediately start anti-osteoporosis treatment
- Diagnosis：Osteoporosis (hip/vertebral fragility fracture; diagnosable without BMD)
- Fracture risk：Very high
- Drug direction：Very high fracture risk: options include teriparatide / zoledronic acid / denosumab / romosozumab (for very high hip risk, prefer zoledronic acid or denosumab)
| Hip or vertebral fragility-fracture history | Absent |
|---|---|
| Fragility fracture at other sites | Absent |
| BMD T-score (lowest site) | -2.7 |
| FRAX 10-year major osteoporotic fracture probability (optional) | 22 % |
| FRAX 10-year hip fracture probability (optional) | 3.5 % |
→DispositionRecommend anti-osteoporosis treatment
- Diagnosis：Osteoporosis (T-score ≤ -2.5)
- Fracture risk：High
- Drug direction：High fracture risk: oral alendronate/risedronate etc.; if oral not tolerated, zoledronic acid or denosumab
Frequently asked questions
- What is Osteoporosis: Starting Anti-Osteoporosis Therapy?
- This tool decides whether to start anti-osteoporosis therapy and at what intensity, integrating fragility-fracture history, BMD T-score, and FRAX 10-year fracture probability.
- How is Osteoporosis: Starting Anti-Osteoporosis Therapy calculated? What is the core formula?
- Treat if hip/vertebral fragility fracture, T ≤ -2.5, or low bone mass (-2.5 < T ≤ -1.0) with another fragility fracture or FRAX major ≥ 20%/hip ≥ 3%. Very high risk (FRAX major > 30%/hip > 4.5%, T ≤ -3.0) selects more potent agents.
- When is Osteoporosis: Starting Anti-Osteoporosis Therapy used?
- Use to triage treatment: a hip/vertebral fragility fracture or T-score ≤ -2.5 mandates therapy, while low bone mass is treated when accompanied by another fragility fracture or high FRAX risk.
- What are the key clinical points for Osteoporosis: Starting Anti-Osteoporosis Therapy?
- A hip or vertebral fragility fracture diagnoses osteoporosis and triggers treatment independent of the BMD value. (original synthesis · not guideline verbatim) Very-high-risk patients are candidates for anabolic or more potent agents (teriparatide, romosozumab, denosumab, zoledronic acid). All patients receive calcium, vitamin D, weight-bearing exercise, fall prevention, and a secondary-cause workup.
- What are the limits and cautions when using Osteoporosis: Starting Anti-Osteoporosis Therapy?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Osteoporosis: Starting Anti-Osteoporosis Therapy calculated in practice? Can you show a worked example?
- Inputs: Hip or vertebral fragility-fracture history Present, Fragility fracture at other sites Present, BMD T-score (lowest site) -2.7, FRAX 10-year major osteoporotic fracture probability (optional) 22 %, FRAX 10-year hip fracture probability (optional) 3.5 % → Result: Disposition Immediately start anti-osteoporosis treatment（Diagnosis: Osteoporosis (hip/vertebral fragility fracture; diagnosable without BMD), Fracture risk: Very high, Drug direction: Very high fracture risk: options include teriparatide / zoledronic acid / denosumab / romosozumab (for very high hip risk, prefer zoledronic acid or denosumab)） Inputs: Hip or vertebral fragility-fracture history Absent, Fragility fracture at other sites Absent, BMD T-score (lowest site) -2.7, FRAX 10-year major osteoporotic fracture probability (optional) 22 %, FRAX 10-year hip fracture probability (optional) 3.5 % → Result: Disposition Recommend anti-osteoporosis treatment（Diagnosis: Osteoporosis (T-score ≤ -2.5), Fracture risk: High, Drug direction: High fracture risk: oral alendronate/risedronate etc.; if oral not tolerated, zoledronic acid or denosumab）